Inventor · disambiguated record
Michael N. Alonso
Also filed as: ALONSO MICHAEL N · ALONSO MICHAEL NATHANIEL
4 granted patents·25 pending applications·8 citations·filing 2018–2025
68Inventor score
Top patents by PatentIndex Score
29 records- 0192US11110178B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 7, 2021·3 cites·30 claims
- 0291US10675358B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Jun 9, 2020·5 cites·30 claims
- 0375US2023111340A1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 0474US11547761B1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jan 10, 2023·0 cites·91 claims
- 0568US11400164B2Immunoconjugates targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2021·Granted Aug 2, 2022·0 cites·44 claims
- 0666US2022347311A1Immunoconjugates Targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0762US2020108151A1Antibody adjuvant conjugatesBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0861US2022195066A1Anti-cea immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0961US2025263392A1Aminobenzazepine compounds, immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1060US2025127914A1Antibody-conjugated 8-sulfonyl-benzazepine compounds and their usesBOLT BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1158US2025145575A1Macromolecule-supported 8-sulfonyl-benzazepine compounds and their usesBOLT BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1257US2019015516A1Antibody adjuvant conjugatesBOLT BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1356US2025000995A1Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1453US2024033370A1Anti-pd-l1 immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1553US2020390899A1Aminobenzazepine compounds, immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1653US2024238430A1Anti-cea immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1752US2024042050A1Anti-her2 immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1852US2024091370A1Anti-her2 immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1951US2023069055A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2051US2023165968A1Cancer treatment methodsBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2149US2023086603A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2246US2022152215A1Immunoconjugates Targeting CEABOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2346US2022226492A1Immunoconjugates Targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2446US2022226491A1Immunoconjugates Targeting PD-L1BOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2546US2022143012A1Macromolecule-Supported TLR AgonistsBOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2646US2021187115A1Immunoconjugates Targeting EGFRBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2745US2021154316A1ImmunoconjugatesBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2843US2020140556A1Methods and Compositions for Dectin-2 Stimulation and Cancer ImmunotherapyUNIV LELAND STANFORD JUNIOR·Filed 2018·Application pending·0 cites
- 2939US2021284750A1Immunoconjugate Synthesis MethodBOLT BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael N. Alonso files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →